

Three-dimensional Radiotherapy

*This measure is to be reported **once per episode**¹ of radiation therapy for all male patients, regardless of age, with clinically localized prostate cancer who receive external beam radiotherapy to the prostate during the reporting period.*

Measure description

Percentage of patients, regardless of age, with a diagnosis of clinically localized prostate cancer receiving external beam radiotherapy as a primary therapy to the prostate with or without nodal irradiation (no metastases; no salvage therapy) who receive three-dimensional conformal radiotherapy (3D-CRT) or intensity modulated radiation therapy (IMRT)

What will you need to report for each male patient with clinically localized prostate cancer receiving external beam radiotherapy for this measure?

If you select this measure for reporting, you will report:

- Whether or not the patient is receiving external beam radiotherapy as primary therapy to the prostate or as adjuvant or salvage therapy

If the patient is receiving external beam radiotherapy as primary therapy (no metastases; no salvage therapy) to prostate, you will then need to report:

- Whether or not the patient received three-dimensional conformal radiotherapy (3D-CRT) or intensity modulated radiation therapy (IMRT)

What if this process or outcome of care is not appropriate for your patient?

Some measures provide an opportunity for the physician or eligible health professional to document when a process or outcome of care is not appropriate for a given patient (also called performance exclusions). Because this measure is applicable to most if not all patients, there are no allowable performance exclusions.

¹Each episode of radiation therapy in an eligible patient receiving external beam radiotherapy to the prostate occurring during the reporting period will be counted when calculating the reporting and performance rates. The PQRI quality code needs to be submitted only once during the episode of radiation therapy (eg, 8 weeks of therapy).